Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
Would you hold HAI/ FUDR for SBRT of a residual liver metastasis following hepatic metastasectomy?
No further systemic therapy is planned for the time being.
Related Questions
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
Is there data to support worse surgical outcomes in short course RT followed by surgery vs. long course chemoradiation followed by surgery in rectal cancer?
How would you treat an MMR-proficient T2 N0 low-rectal cancer (measuring 2 cm extending 4-6 cm from the anal verge) in a patient who wishes to preserve his sphincter?
How was treatment response assessed on the PROSPECT trial?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?
Would you consider long course pelvic CRT after neoadjuvant chemotherapy in a patient with low lying, locally advanced rectal adenocarcinoma when you're unable to meet small bowel constraints?
When treating primary liver disease with radiation, how do you contour and constrain the central bile ducts?
Do you use different dose constraints for large bowel vs. small bowel?